August 2003: 47‐year‐old female with a 7‐year history of osteomalacia and hypophosphatemia

The August 2003 COM. A 47-year-old woman presented with a long history of muscle pain, weakness, and visual disturbances. Over the last year, she developed diplopia and left sixth nerve palsy. No other neuro-ophthalmologic abnormalities were found. Past medical and family history was unremarkable. Laboratory investigation disclosed hypophosphatemia, phosphaturia, elevated serum alkaline phosphatase activity, and normal serum calcium levels. CT scans showed a lobulated mass arising on the meningeal surface of the cavernous sinus, measuring 3x 2 x 2 cm. The lesion was partially resected and microscopic examination revealed a highly vascularized tumor composed of primitive mesenchymal cells arranged whether in a patternless-pattern or surrounding thin-walled, branching vascular spaces and thick-walled hyalinized vessels. Other eye-catching features were microcystic areas, multinucleated osteoclastic-like giant cells, scattered islands of mature adipocytes, foci of hemorrhage, thrombosed medium-sized-to-large vessels, and hemosiderin-laden macrophages. After surgery, the patient recovered from the muscle pain and weakness, with a significant improvement of serum calcium and alkaline phosphatase levels and phosphate blood levels. Taken together, the clinical and pathologic features were consistent with a diagnosis of phosphaturic mesenchymal tumor (mixed connective tissue variant) of the cavernous sinus in a setting of oncogenic osteomalacia. No further treatment was carried out. The patient has been followed for the last 4 years with no evidence of recurrent disease. Oncogenic osteomalacia is a rare clinical entity characterized by hypophosphatemia, phosphaturia, and a low concentration of 1,25-dihydroxyvitamin D(3) caused by a neoplasm. Pathologists should be aware of this entity, because surgical excision of the tumor is usually curative.

[1]  S. Jan de Beur Tumor-induced osteomalacia. , 2005, JAMA.

[2]  R. Martuza,et al.  Craniofacial Hemangiopericytoma Associated with Oncogenic Osteomalacia: Case Report , 2004, Journal of Neuro-Oncology.

[3]  G. Strewler FGF23, hypophosphatemia, and rickets: Has phosphatonin been found? , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[4]  S. Takeda,et al.  Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[5]  T. Spector,et al.  The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. , 2001, The Journal of clinical endocrinology and metabolism.

[6]  A. Gascón,et al.  Oncogenic osteomalacia in a patient with a fibrocystic nodule of the breast. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  N. Weidner Review and update: oncogenic osteomalacia-rickets. , 1991, Ultrastructural pathology.

[8]  N. Weidner,et al.  Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets , 1987, Cancer.

[9]  N. Weidner,et al.  Neoplastic pathology of oncogenic osteomalacia/rickets , 1985, Cancer.